Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Authors
Keywords
Chronic lymphocytic leukemia (CLL), Effectiveness, First-line, Ibrutinib, Real-world, Relapsed/refractory (R/R)
Journal
Clinical Lymphoma Myeloma & Leukemia
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-08-04
DOI
10.1016/j.clml.2021.07.022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative
- (2021) Francesc Bosch et al. ANNALS OF HEMATOLOGY
- Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study
- (2020) John C. Byrd et al. CLINICAL CANCER RESEARCH
- Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study
- (2020) BARTOSZ PULA et al. ANTICANCER RESEARCH
- Real‐World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
- (2020) Kathrine Aarup et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
- (2019) Susan M. O'Brien et al. AMERICAN JOURNAL OF HEMATOLOGY
- Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
- (2019) Kerry A. Rogers et al. LEUKEMIA
- Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
- (2019) Thomas J. Kipps et al. Clinical Lymphoma Myeloma & Leukemia
- Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece
- (2019) Maria Dimou et al. LEUKEMIA & LYMPHOMA
- Chronic lymphocytic leukaemia: from genetics to treatment
- (2019) Francesc Bosch et al. Nature Reviews Clinical Oncology
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
- (2019) Gilles Salles et al. ANNALS OF HEMATOLOGY
- Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results from the informCLL™ Registry
- (2019) Anthony R. Mato et al. Clinical Lymphoma Myeloma & Leukemia
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- (2018) Michael Hallek et al. BLOOD
- Safety Analysis of 4 Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
- (2018) Susan O'Brien et al. Clinical Lymphoma Myeloma & Leukemia
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
- (2018) Anthony R. Mato et al. AMERICAN JOURNAL OF HEMATOLOGY
- Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- (2018) Jacqueline C. Barrientos et al. Clinical Lymphoma Myeloma & Leukemia
- Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort
- (2018) Maria Winqvist et al. HAEMATOLOGICA
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2018) G. Fraser et al. LEUKEMIA
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
- (2017) F Nadeu et al. LEUKEMIA
- Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)
- (2017) Elżbieta Iskierka-Jażdżewska et al. LEUKEMIA & LYMPHOMA
- Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies
- (2017) AnnaLynn M. Williams et al. LEUKEMIA & LYMPHOMA
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
- (2017) Jennifer R. Brown et al. HAEMATOLOGICA
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia
- (2016) Davide Rossi et al. LEUKEMIA & LYMPHOMA
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Perturbation of the normal immune system in patients with CLL
- (2015) F. Forconi et al. BLOOD
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
- (2015) C. Sun et al. BLOOD
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
- (2014) C. S. Tam et al. BLOOD
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression
- (2011) C. Nunes et al. CLINICAL CANCER RESEARCH
- Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2011) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
- (2010) Tadeusz Robak et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started